Yıl: 2021 Cilt: 2 Sayı: 3 Sayfa Aralığı: 91 - 96 Metin Dili: İngilizce DOI: 10.51271/jpea-2021-0145 İndeks Tarihi: 28-11-2022

Fertility Preservation Methods in Childhood and Adolescence Cancers: A Review

Öz:
In childhood and adolescence cancers; survival rates increase with the use of treatment options such as hematopoietic stem cell transplantation, chemotherapy and radiotherapy. One of the long-term effects of primary disease and cancer treatment is the irreversible damage to gonadal tissues, resulting in impaired fertility. Especially chemotherapeutic drugs; causes germ cell defect, affects the secretion of pituitary hormone, and also damages the anatomical structures of internal genital structures such as the uterus.Gonadal preservation methods are limited in prepubertal male patients. It is a good option to place the testicles in a different area before radiotherapy. Before chemotherapy or whole body irradiation, freezing of testicular tissue and ensuring pregnancy from frozen tissue is still in the experimental stage. After the ejaculation begins, obtaining and storing sperm is successfully done. A limited number of pregnancies were obtained oocytes frozen ovaries in the prepubertal girls. It is possible to freeze oocytes after puberty begins. In addition, recently, as a noninvasive method, gonadotropin-releasing hormone (GnRH) analogues have been used successfully, as it suppresses the hypothalamic-pituitary-gonadal axis and protects germ cells from cytotoxic effects. This article aims to provide information on fertility preservation methods in patients receiving childhood cancer treatment
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7-30. [CrossRef]
  • 2. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered? Lancet Oncol. 2005;6:209-218. [CrossRef]
  • 3. Rafsanjani KA, Faranoush M, Hedayatiasl AA, Vossough P. Gonadal function and fertility in male survivors treated for Hodgkin's disease in Iran. Saudi Med J. 2007;28:1690-1693. [CrossRef]
  • 4. Green DM, Liu W, Kutteh WH, et al. Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. Lancet Oncol. 2014;15:1215-1223. [CrossRef]
  • 5. Wallace WH. Oncofertility and preservation of reproductive capacity in children and young adults. Cancer. 2011;117:2301- 2310. [CrossRef]
  • 6. George SA, Williamson Lewis R, Schirmer DA, et al. Early Detection of Ovarian Dysfunction by Anti-Mullerian Hormone in Adolescent and Young Adult-Aged Survivors of Childhood Cancer. J Adolesc Young Adult Oncol. 2019;8:18-25. [CrossRef]
  • 7. Chemaitilly W, Mertens AC, Mitby P, et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab. 2006;91:1723-1728. [CrossRef]
  • 8. Trudgen K, Ayensu-Coker L. Fertility preservation and reproductive health in the pediatric, adolescent, and young adult female cancer patient. Curr Opin Obstet Gynecol. 2014;26:372- 380. [CrossRef]
  • 9. Chemaitilly W, Sklar CA. Endocrine complications in long- term survivors of childhood cancers. Endocr Relat Cancer. 2010;17:R141-R159. [CrossRef]
  • 10. Green DM, Sklar CA, Boice JD Jr, et al. Ovarian failure and reproductive outcomes after childhood cancer treatment: results from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27:2374-2381. [CrossRef]
  • 11. Tauchmanovà L, Selleri C, De Rosa G, et al. Gonadal status in reproductive age women after haematopoietic stem cell transplantation for haematological malignancies. Hum Reprod. 2003;18:1410-1416. [CrossRef]
  • 12. Seppänen VI, Artama MS, Malila NK, et al. Risk for congenital anomalies in offspring of childhood, adolescent and young adult cancer survivors. Int J Cancer. 2016;139:1721-1730. [CrossRef]
  • 13. Sayan M, Cassidy RJ, Butker EE, et al. Gonadal shielding technique to preserve fertility in male pediatric patients treated with total body irradiation for stem cell transplantation. Bone Marrow Transplant. 2016;51:997–998. [CrossRef]
  • 14. Fayomi AP, Peters K, Sukhwani M, et al. Autologous grafting of cryopreserved prepubertal rhesus testis produces sperm and offspring. Science. 2019;363:1314-1319. [CrossRef]
  • 15. Wyns C, Curaba M, Vanabelle B, Van Langendonckt A, Donnez J. Options for fertility preservation in prepubertal boys. Hum Reprod Update. 2010;16:312-328. [CrossRef]
  • 16. Valli-Pulaski H, Peters KA, Gassei K, et al. Testicular tissue cryopreservation: 8 years of experience from a coordinated network of academic centers. Hum Reprod. 2019;34:966-977. [CrossRef]
  • 17. Radford J. Restoration of fertility after treatment for cancer. Horm Res. 2003;59:21-23. [CrossRef]
  • 18. Ntemou E, Kadam P, Van Laere S, Van Saen D, Vicini E, Goossens E. Effect of recombinant human vascular endothelial growth factor on testis tissue xenotransplants from prepubertal boys: a three- case study. Reprod Biomed Online. 2019;39:119-133. [CrossRef]
  • 19. Salama M, Anazodo A, Woodruff TK. Preserving fertility in female patients with hematological malignancies: a multidisciplinary oncofertility approach. Ann Oncol. 2019;30:1760-1775. [CrossRef]
  • 20. Michalczyk K, Cymbaluk-Płoska A. Fertility Preservation and Long-Term Monitoring of Gonadotoxicity in Girls, Adolescents and Young Adults Undergoing Cancer Treatment. Cancers (Basel). 2021;13:202. [CrossRef]
  • 21. Armstrong AG, Kimler BF, Smith BM, Woodruff TK, Pavone ME, Duncan FE. Ovarian tissue cryopreservation in young females through the Oncofertility Consortium's National Physicians Cooperative. Future Oncol. 2018;14:363-378. [CrossRef]
  • 22. Poirot C, Vacher-Lavenu MC, Helardot P, Guibert J, Brugières L, Jouannet P. Human ovarian tissue cryopreservation: indications and feasibility. Hum Reprod. 2002;17:1447-1452. [CrossRef]
  • 23. Meirow D, Ra'anani H, Shapira M, et al. Transplantations of frozen- thawed ovarian tissue demonstrate high reproductive performance and the need to revise restrictive criteria. Fertil Steril. 2016;106:467- 474. [CrossRef]
  • 24. Matthews SJ, Picton H, Ernst E, Andersen CY. Successful pregnancy in a woman previously suffering from β-thalassemia following transplantation of ovarian tissue cryopreserved before puberty. Minerva Ginecol. 2018;70:432-435. [CrossRef]
  • 25. Meirow D, Levron J, Eldar-Geva T, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med. 2005;353:318- 321. [CrossRef]
  • 26. Silber S. Ovarian tissue cryopreservation and transplantation: scientific implications. J Assist Reprod Genet. 2016;33:1595-1603. [CrossRef]
  • 27. Rosendahl M, Andersen MT, Ralfkiær E, Kjeldsen L, Andersen MK, Andersen CY. Evidence of residual disease in cryopreserved ovarian cortex from female patients with leukemia. Fertil Steril. 2010;94:2186-2190. [CrossRef]
  • 28. Aubard Y, Piver P, Pech JC, Galinat S, Teissier MP. Ovarian tissue cryopreservation and gynecologic oncology: a review. Eur J Obstet Gynecol Reprod Biol. 2001;97:5-14. [CrossRef]
  • 29. Eghbali H, Papaxanthos-Roche A. The impact of lymphoma and treatment on male fertility. Expert Rev Hematol. 2010;3:775-788. [CrossRef]
  • 30. Schmiegelow ML, Sommer P, Carlsen E, Sønksen JO, Schmiegelow K, Müller JR. Penile vibratory stimulation and electroejaculation before anticancer therapy in two pubertal boys. J Pediatr Hematol Oncol. 1998;20:429-430. [CrossRef]
  • 31. Tesarik J, Bahceci M, Ozcan C, Greco E, Mendoza C. Restoration of fertility by in-vitro spermatogenesis. Lancet. 1999;353:555-556. [CrossRef]
  • 32. Sofikitis N, Mantzavinos T, Loutradis D, Yamamoto Y, Tarlatzis V, Miyagawa I. Ooplasmic injections of secondary spermatocytes for non-obstructive azoospermia. Lancet. 1998;351:1177-1178. [CrossRef]
  • 33. Habermann H, Seo R, Cieslak J, Niederberger C, Prins GS, Ross L. In vitro fertilization outcomes after intracytoplasmic sperm injection with fresh or frozen-thawed testicular spermatozoa. Fertil Steril. 2000;73:955-960. [CrossRef]
  • 34. Kotzur T, Benavides-Garcia R, Mecklenburg J, Sanchez JR, Reilly M, Hermann BP. Granulocyte colony-stimulating factor (G-CSF) promotes spermatogenic regeneration from surviving spermatogonia after high-dose alkylating chemotherapy. Reprod Biol Endocrinol. 2017;15:7. [CrossRef]
  • 35. Zhang X, Xia Q, Wei R, et al. Melatonin protects spermatogonia from the stress of chemotherapy and oxidation via eliminating reactive oxidative species. Free Radic Biol Med. 2019;137:74-86. [CrossRef]
  • 36. Cobo A, García-Velasco JA, Coello A, Domingo J, Pellicer A, Remohí J. Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril. 2016;105:755-764.e8. [CrossRef]
  • 37. ACOG: Committee Opinion No. 584: oocyte cryopreservation. Obstet Gynecol. 2014;123:221-222. [CrossRef]
  • 38. Oktem O, Oktay K. Fertility preservation for breast cancer patients. Semin Reprod Med. 2009;27:486-492. [CrossRef]
  • 39. Noyes N, Porcu E, Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online. 2009;18:769-776. [CrossRef]
  • 40. Demeestere I, Simon P, Dedeken L, et al. Live birth after autograft of ovarian tissue cryopreserved during childhood. Hum Reprod. 2015;30:2107-2109. [CrossRef]
  • 41. Gellert SE, Pors SE, Kristensen SG, Bay-Bjørn AM, Ernst E, Yding Andersen C. Transplantation of frozen-thawed ovarian tissue: an update on worldwide activity published in peer- reviewed papers and on the Danish cohort. J Assist Reprod Genet. 2018;35:561-570. [CrossRef]
  • 42. Meistrich ML, Shetty G. Hormonal suppression for fertility preservation in males and females.Reproduction. 2008;136:691- 701. [CrossRef]
  • 43. Oktay K, Harvey BE, Partridge AH, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36:1994-2001. [CrossRef]
  • 44. Lambertini M, Falcone T, Unger JM, Phillips KA, Del Mastro L, Moore HC. Debated Role of Ovarian Protection With Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Women With Cancer. J Clin Oncol. 2017;35:804-805. [CrossRef]
  • 45. Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015;26:2408-2419. [CrossRef]
  • 46. Shen YW, Zhang XM, Lv M, et al. Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis. Onco Targets Ther. 2015;8:3349-3359. [CrossRef]
  • 47. Del Mastro L, Ceppi M, Poggio F, et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev. 2014;40:675-683. [CrossRef]
  • 48. Wang C, Chen M, Fu F, Huang M. Gonadotropin-Releasing Hormone Analog Cotreatment for the Preservation of Ovarian Function during Gonadotoxic Chemotherapy for Breast Cancer: A Meta-Analysis. PLoS One. 2013;8:e66360. [CrossRef]
  • 49. Elgindy E, Sibai H, Abdelghani A, Mostafa M. Protecting Ovaries During Chemotherapy Through Gonad Suppression: A Systematic Review and Meta-analysis. Obstet Gynecol. 2015;126:187-195. [CrossRef]
  • 50. Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372:923-932. [CrossRef]
  • 51. Blumenfeld Z, Patel B, Leiba R, Zuckerman T. Gonadotropin- releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation. Fertil Steril. 2012;98:1266-70.e1. [CrossRef]
  • 52. AIOM. Linee guida per la preservazione della fertilità nei pazienti oncologici. Italian Association of Medical Oncology (AIOM) (2020).
  • 53. National Comprehensive Cancer Network (NCCN) Guidelines. Available at: [CrossRef] (Accessed January 2021).
  • 54. Oktay K, Harvey BE, Partridge AH, et al. Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018;36:1994-2001. [CrossRef]
  • 55. Dolmans MM, Taylor HS, Rodriguez-Wallberg KA, et al. Utility of gonadotropin-releasing hormone agonists for fertility preservation in women receiving chemotherapy: pros and cons. Fertil Steril. 2020;114:725-738. [CrossRef]
APA SİRAZ Ü, Hatipoglu N (2021). Fertility Preservation Methods in Childhood and Adolescence Cancers: A Review. , 91 - 96. 10.51271/jpea-2021-0145
Chicago SİRAZ Ülkü Gül,Hatipoglu Nihal Fertility Preservation Methods in Childhood and Adolescence Cancers: A Review. (2021): 91 - 96. 10.51271/jpea-2021-0145
MLA SİRAZ Ülkü Gül,Hatipoglu Nihal Fertility Preservation Methods in Childhood and Adolescence Cancers: A Review. , 2021, ss.91 - 96. 10.51271/jpea-2021-0145
AMA SİRAZ Ü,Hatipoglu N Fertility Preservation Methods in Childhood and Adolescence Cancers: A Review. . 2021; 91 - 96. 10.51271/jpea-2021-0145
Vancouver SİRAZ Ü,Hatipoglu N Fertility Preservation Methods in Childhood and Adolescence Cancers: A Review. . 2021; 91 - 96. 10.51271/jpea-2021-0145
IEEE SİRAZ Ü,Hatipoglu N "Fertility Preservation Methods in Childhood and Adolescence Cancers: A Review." , ss.91 - 96, 2021. 10.51271/jpea-2021-0145
ISNAD SİRAZ, Ülkü Gül - Hatipoglu, Nihal. "Fertility Preservation Methods in Childhood and Adolescence Cancers: A Review". (2021), 91-96. https://doi.org/10.51271/jpea-2021-0145
APA SİRAZ Ü, Hatipoglu N (2021). Fertility Preservation Methods in Childhood and Adolescence Cancers: A Review. The journal of pediatric academy (Online), 2(3), 91 - 96. 10.51271/jpea-2021-0145
Chicago SİRAZ Ülkü Gül,Hatipoglu Nihal Fertility Preservation Methods in Childhood and Adolescence Cancers: A Review. The journal of pediatric academy (Online) 2, no.3 (2021): 91 - 96. 10.51271/jpea-2021-0145
MLA SİRAZ Ülkü Gül,Hatipoglu Nihal Fertility Preservation Methods in Childhood and Adolescence Cancers: A Review. The journal of pediatric academy (Online), vol.2, no.3, 2021, ss.91 - 96. 10.51271/jpea-2021-0145
AMA SİRAZ Ü,Hatipoglu N Fertility Preservation Methods in Childhood and Adolescence Cancers: A Review. The journal of pediatric academy (Online). 2021; 2(3): 91 - 96. 10.51271/jpea-2021-0145
Vancouver SİRAZ Ü,Hatipoglu N Fertility Preservation Methods in Childhood and Adolescence Cancers: A Review. The journal of pediatric academy (Online). 2021; 2(3): 91 - 96. 10.51271/jpea-2021-0145
IEEE SİRAZ Ü,Hatipoglu N "Fertility Preservation Methods in Childhood and Adolescence Cancers: A Review." The journal of pediatric academy (Online), 2, ss.91 - 96, 2021. 10.51271/jpea-2021-0145
ISNAD SİRAZ, Ülkü Gül - Hatipoglu, Nihal. "Fertility Preservation Methods in Childhood and Adolescence Cancers: A Review". The journal of pediatric academy (Online) 2/3 (2021), 91-96. https://doi.org/10.51271/jpea-2021-0145